Background: Genetic aetiology of pheochromocytoma (PCC) and paraganglioma (PGL) is increasingly being studied; however, Asian Indian data on this aspect are scarce. Objective: To study the prevalence of germline mutations and genotype-phenotype correlation in Asian Indian PCC/ PGL patients. Design: In this study, 150 index patients (M:F, 73:77) with PCC/PGL were evaluated. Phenotypic data were collected. Germline mutations in five susceptibility genes (RET, VHL, SDHB, SDHD and SDHC) were tested by sequencing and NF1 was diagnosed according to phenotype. Result: Of the total population, 49 (32.7%) PCC/PGL patients had germline mutations (VHL: 23 (15.3%), RET: 13 (8.7%), SDHB: 9 (6%), SDHD: 2 (1.3%) and NF1: 2 (1.3%)). Amongst the 30 patients with familial and/or syndromic presentation, all had germline mutations (VHL: 14 (46.7%), RET: 13 (43.3%), SDHB: 1 (3.3%) and NF1: 2 (6.7%)). Out of 120 patients with apparently sporadic presentation, 19 (15.8%) had a germline mutation (VHL: 9 (7.5%), SDHB: 8 (6.7%) and SDHD: 2 (1.7%)). Mutation carriers were younger (29.9 ± 14.5 years vs 36.8 ± 14.9; P = 0.01) and had a higher prevalence of bilateral PCC (26.5% vs 2.9%, P < 0.001) and multifocal tumours (12.2% vs 0.96%, P = 0.06). Based on syndromic features, metastasis, location and number of tumours, around 96% mutations in our cohort could be detected by appropriately selected single gene testing. Conclusion: Asian Indians with PCC/PGL differ from Western cohorts in having preponderance of VHL mutations in multifocal tumours and apparently sporadic unilateral PCC. Syndromic presentation, metastasis, location and number of PCC/PGL can be effectively used for guiding genetic prioritisation.
Introduction
Pheochromocytoma (PCC) and paraganglioma (PGL) are tumours derived from neural crest cells located in the adrenal medulla and sympathetic/parasympathetic ganglia respectively (1) . PCC and sympathetic PGL (sPGL) generally secrete catecholamines responsible for classic symptoms, whereas head and neck PGL (HNPGL) that arise from parasympathetic ganglia are usually non-secretory (1) .
Since 1990, germline mutations have been reported in 16 PCC/PGL susceptibility genes: NF1 (2), RET (3), VHL (4), SDHD (5), SDHC (6) , SDHB (7), TMEM127 (8) , MAX (9) , SDHAF2 (10), SDHA (11) , FH (12) , EGLN1 (13) , EGLN2 (14) , MDH2 (15) , KIF1BB (16) and EPAS1 (17) . Germline mutations in genes such as VHL, RET and NF1 have been characterised by typical syndromic components, making their genetic diagnosis easier. The prevalence of germline mutations in PCC/PGL patients with familial and/or syndromic (FS) presentation has been high as expected; however, the genetic yield in patients with apparently sporadic (AS) presentation has always attracted attention. In 2002, Neumann et al. reported germline mutations (VHL, RET, SDHB and SDHD) in 66 (24%) of 271 PCC/PGL patients with AS presentation, thus ending the 10% rule of hereditary PCC (18) . Following this initial report from Germany, analysis of these genes in large PCC/PGL cohorts from other parts of the world also reported a similar yield (19, 20, 21, 22) . A recent systematic review reported a germline mutation rate of 11.6% in 5031 PCC/PGL patients with AS presentation (23) , ultimately paving the way for the Endocrine Society recommendation of genetic testing of all patients with PCC/PGL (24) .
The pursuit of studying genetic aetiology is important for understanding the pathophysiology of the disorder, investigating targeted therapy and genetic counselling. Due to the implications of multiple genes and the cost and labour involved in Sanger sequencing, a clinical feature-driven diagnostic algorithm should be established to guide the prioritisation of genetic testing (24) .
Genetic aetiology of PCC/PGL is increasingly being studied; however, Indian data on genotypephenotype correlation are scarce. Our objective is to study the prevalence of germline mutations in the major susceptibility genes (VHL, RET, SDHB, SDHD, SDHC and NF1) and genotype-phenotype correlation in Asian Indian patients with PCC/PGL.
Subjects and methods
A total of 150 unrelated index patients with PCC/PGL (functional and non-functional) attending the endocrine clinics of eight different centres (120 from Seth G.S. Medical College and K.E.M. Hospital, Mumbai, and 30 from collaborating centres) from India were included in the study. Institutional ethics committee approved the study, and a written informed consent was obtained from all participants. Diagnosis of PCC/PGL was based on surgical histology in 136 patients. In patients for whom surgical histology was not available, the diagnosis was based on plasma free metanephrines, functional imaging ( 131 I-metaiodobenzylguanidine (MIBG)) and anatomical imaging (Computed tomography (CT) in PCC and sPGL, magnetic resonance imaging (MRI) in HNPGL).
A detailed personal and family history was elicited in all patients for familial/syndromic association. Patients were evaluated for catecholamine excess status with 24-h urinary vanillylmandelic acid and/or plasma-free metanephrines. Twenty four hour urinary vanillylmandelic acid > 10 mg, plasma-free normetanephrine > 180 pg/mL or plasma-free metanephrine > 90 pg/mL were considered as elevated and tumours were considered as hormonally functional. Tumours with normal biochemistry were considered as non-functional. Tumours with isolated elevation of plasma normetanephrine were considered as normetanephrine secreting, whereas those with elevation of plasma metanephrine with or without elevation of plasma normetanephrine were considered as metanephrine secreting. Patients underwent anatomical imaging (computed tomography of neck to pelvis) and functional imaging ( 131 I-metaiodobenzylguanidine). Head and neck PGL patients were also subjected to MRI of head and neck. Computed tomography of the abdomen was examined for components of VHL (renal cysts and renal cell carcinoma, pancreatic cysts and pancreatic neuroendocrine tumours). Clinical diagnosis of neurofibromatosis 1 (NF1) was based on the established clinical criteria (25) .
Familial/syndromic (FS) group was characterised by the presence of stigmata of known syndrome in the index case/family members, and/or history of PCC/PGL in family members. Absence of FS characteristics was considered as apparently sporadic (AS). Tumours were classified into mutually exclusive groups as PCC: unilateral/ bilateral, sPGL: single/multiple, HNPGL: unilateral/ bilateral and multifocal disease (coexistence of PCC and PGL). Metastatic disease was defined as the presence of lesions outside the adrenal glands and sympathetic and parasympathetic chain.
Genotype analysis
Genomic DNA was extracted from the peripheral blood using alcohol precipitation method. All patients were screened for pathogenic variations in five genes by 
Results

Phenotype
Overall, 150 unrelated index patients were enrolled in the study (77 females and 73 males). The mean age at presentation was 34.5 ± 14.8 years (age range, 6-75 years). (10) , splice site mutation (1), deletion (1), duplication (1) and large deletions (2)) were identified, of which five were novel ( Table 2 ). The mean age of presentation was 25.9 ± 14.6 (range: 6-55) years, with 14 patients (60.8%) having FS presentation and nine (39.1%) having AS presentation. Plasma-free metanephrines were available for 14 patients and all had isolated elevation of plasma normetanephrine. Of 23 patients, 18 (78.3%) had PCC (bilateral: 6, unilateral: 12) and five (21.7%) had multifocal disease (PCC with sPGL). The mean tumour size was 5.3 ± 2.5 (range: 2-8.7) cm. There was no evidence of malignant disease.
RET mutations
There were 13 patients with RET mutations of which ten had mutations in codon 634 (MEN 2A) and three had mutations in codon 918 (MEN 2B). The mean age of presentation was 40.4 ± 14.6 (range: 22-58) years with all patients having past or present evidence of medullary thyroid carcinoma. Cutaneous lichen amyloidosis and primary hyperparathyroidism were observed in three and two patients with MEN2A respectively. All patients with MEN2B had characteristic phenotypic features including Marfanoid habitus, mucosal neuromas and fleshy lips. The mean tumour size was 5.5 ± 2.5 (range: 4-7.2) cm. Plasma-free metanephrines were available for eight patients and all had elevation of both metanephrine and normetanephrine. Twelve (92.3%) patients had PCC, with bilateral PCC in seven. One MEN2A patient had a multifocal (bilateral PCC with an abdominal sPGL) malignant disease, which was unusual for RET phenotype. Apart from RET, we performed PCR for VHL, SDHB, SDHC, SDHD as well as MLPA for VHL and SDHx in this patient and could not find a second mutation.
SDHB mutations
In nine patients, nine different SDHB mutations (missense mutations (7), splice site mutation (1) and deletion (1)) were identified, of which four were novel ( Table 2 ). The mean age of presentation was 25.4 ± 8.1 (range: 13-38) years, with a majority of patients (8/9, 88.9%) having AS presentation. The mean tumour size was 5.9 ± 1.9 (range: 3-9) cm. Plasma-free metanephrines were available for five patients, and all had isolated elevation of plasma normetanephrine. Tumours were mostly sPGL (8/9, 88.9%), with one patient having two abdominal sPGLs. None of the patients had multifocal disease, and only one had unilateral PCC. Of nine patients, two (22.2%) had an evidence of metastatic disease. Amongst the 16 patients with malignant tumours, three (18.8%) harboured a germline mutation of which two were in SDHB.
SDHD mutations
SDHD mutations were identified in two patients; both were deletions (one novel). The mean age of presentation was 20 ± 2.8 years, with both having AS presentation.
Of the two patients, one had a unilateral PCC, whereas the other had bilateral HNPGL. There was no evidence of multifocality or malignancy.
NF1 patients
The diagnosis of NF1 was based only on established clinical criteria without performing genetic analysis of NF1 gene. Both patients with NF1 had classical cutaneous lesions (café au lait pigmented spots and neurofibromas). The average age at presentation of the two patients was 37.5 ± 10.6 years and both had benign unilateral PCC.
Mutation-negative group
Mutation-negative group included 101 patients with all patients having an AS presentation. The mean age at presentation was 36.8 ± 14.8 (range: 8-75) years. Plasmafree metanephrines were available for 74 patients, of which 40 were normetanephrine secreting, 23 were metanephrine secreting and the rest were non-secretory; 69 (68.3%) patients had PCC (bilateral: 3, unilateral: 66), 22 (21.8%) had sPGL (multiple: 3, single: 19), nine (8.9%) had HNPGL (bilateral: 1) and one (1%) had multifocal disease. The mean tumour size was 6.2 ± 2.4 (range: 2.3-22) cm; 13 (12.9%) patients had metastatic disease.
Genotype-phenotype correlation
Patients with VHL and SDHB mutations were younger than those with RET mutations (P = 0.004, P = 0.017 respectively) and those in the mutation-negative group (P < 0.001, P = 0.025 respectively). FS presentation was more common in patients with RET compared with VHL (P < 0.001), SDHB (P < 0.001) and mutation-negative group (P < 0.001). Mutation-negative group had a significantly greater proportion of unilateral PCC compared with RET (P = 0.024) and SDHB (P = 0.002) mutation groups. Patients with mutations had a greater proportion of bilateral PCC (26.5% vs 3%, P < 0.001) compared with no mutation group. Amongst the mutation-positive group, patients with RET mutations had a significantly greater proportion of bilateral PCC than those with VHL mutations (P = 0.004) and SDHB mutations (P < 0.001).
Patients with mutations had a greater proportion of multifocal (12.3% vs 1%, P = 0.06) compared with no mutation group. Amongst the mutation-positive group, multifocal tumours were significantly more common in patients with VHL mutations than patients with RET mutations (P = 0.046) and SDHB mutations (P = 0.007). sPGLs were frequent in patients with SDHB mutations compared with those with VHL mutations (P < 0.001), RET mutations (P < 0.001) and no mutation group (P < 0.001) ( Table 3) .
Discussion
In this largest Asian Indian PCC/PGL cohort, we report germline mutations in 32.7% of the total patients, which is comparable with the reported cohorts (27.4-39.2%) as shown in Table 4 (18, 19, 20, 22) . The genetic yield in patients with FS presentation was high (100%) as reported from previous studies (92.7-100%) (19, 20, 22) . VHL and RET constituted 90% of the mutations in the FS group. Similar preponderance of VHL and RET genes (55.4-87.1%) has been reported in FS group in previous large PCC/PGL cohorts (18, 19, 22) . The genetic yield in patients with AS presentation (15.8%) was similar to that in previous studies (11.6-17.2%) (18, 19, 20, 22) . The most common mutations in AS group were in VHL and SDHB (89.5%). Similar preponderance of VHL and SDHB genes (77.1-90%) has been reported in the literature (18, 19, 20) .
Our patients with hereditary disease were younger than those with no mutations. Association of hereditary PCC/PGL with younger age is a universal finding in all previous studies (18, 19, 20, 21, 22) . Initial studies rather suggested restriction of genetic testing to younger patients. In our cohort, the genetic yield in patients with AS presentation older than 46 years was 4% (1/25) and nil in ten patients older than 55 years. Hence, we may consider restricting genetic analysis to PCC/PGL patients younger than 46 years.
Apart from FS presentation, bilateral PCC had the strongest association with the presence of a germline mutation. This has been depicted across almost all major studies with 56.3-87.8% patients with bilateral PCC having germline mutations (19, 21, 22) . VHL and RET mutations account for most of the mutations (77.7-100%) in bilateral PCC, making the genetic prioritisation easier based on typical syndromic presentation. In addition to bilateral PCC, multifocal tumours were also more common in hereditary disease. Interestingly, our patients with multifocal disease (PCC and sPGL) had mutations in VHL (n = 5) and RET (n = 1) but not in SDHB or SDHD. This is in contrast to reports from previous large cohorts where SDHB and SDHD mutations are equally or more commonly reported in patients with coexisting PCC and sPGL (19, 22) . Analysis performed between VHL, RET, SDHB and no mutation group by one-way ANOVA; *P value is non-significant between VHL vs SDHB and RET vs no mutation; † P value is significant between RET vs no mutation and SDHB vs no mutation; ‡ P value is not significant between SDHB vs no mutation; § P is not significant between VHL vs RET and RET vs no mutation; || P value is not significant between RET vs SDHB and RET vs no mutation.
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AS, apparently sporadic presentation; FS, familial/syndromic presentation; HNPGL, head and neck paraganglioma; MN, metanephrine; NMN, normetanephrine; NS, non-secretory; PCC, pheochromocytoma; PGL, paraganglioma; sPGL, sympathetic paraganglioma.
www.eje-online.org Amongst patients with unilateral PCC, 24.1% of patients had mutations, VHL being the most (12/21, 57.1%) affected gene. In previous studies, VHL, RET and NF1 are the commonly affected genes in patients with unilateral PCC. In patients with sPGL, 26.7% of patients had germline mutations and all were in SDHB gene, which is in accordance with the literature (20, 22) . Hence, in patients with sPGL, the first gene of choice should be SDHB. The cases with HNPGL were small in our study with low prevalence of germline mutation (1/10, 10%). However, one of the two patients with bilateral HNPGL had mutation in SDHD gene, which is similar to previous reports favouring prioritisation of SDHD gene testing in bilateral HNPGL (20, 22) .
Although the prevalence of germline mutations was less in patients with malignancy (3/16, 18.8%), majority (19, 20, 22) . The other patient with malignancy had RET mutation (C634Y). This patient had bilateral PCC along with an abdominal extra-adrenal PGL at diagnosis and a year later presented with multiple abdominal metastases. Unusual presentation made us search for a coexisting mutation in other genes, which was negative. Although malignancy is rarely described in patients with RET mutation (34) , rare presence of extra-adrenal tumour in our patient may account for the malignant disease. Amongst single benign tumours with AS presentation, our genetic yield was 14.6% (PCC: 10.8%, sPGL: 24.1%), which is comparable with that reported in a recent systematic review (11-13%; PCC: 7.1%, sPGL: 13.5%) (23) . Amongst the apparently sporadic unilateral PCC with positive mutations, VHL mutations were the most common (6/8, 75%). This is in contrast to a recent systematic review, which reported SDHB as the most common gene involved in apparently sporadic single PCC (23) . Observations similar to our study have also been reported in a previous study from India in which none of the 32 patients with apparently sporadic unilateral PCC had SDHB mutations (35) . Hence, in Asian Indian patients with unilateral PCC with AS presentation, VHL could be the first gene of choice.
In our cohort, there was a strong genotype-phenotype correlation. The evaluation for syndromic components identified 57.1% (VHL (13), RET (13) and NF1 (2)) of all the mutations. Hence, it is of utmost importance to obtain a detailed personal and family history and relevant evaluation for known syndromic stigmata. The additional prioritisation based on the presence of metastasis, location and number of tumour was useful. Exclusive presence of VHL mutations in non-syndromic bilateral PCC and multifocal PCC/PGL, SDHB mutations in sPGL and metastatic tumours, and SDHD mutation in bilateral HNPGL provided an opportunity to identify 26.5% (VHL (4), SDHB (8) and SDHD (1)) of all the mutations. Further genetic testing for VHL in unilateral PCC identified another six (12.2%) mutations. Overall, an appropriately selected single gene testing could identify around 96% of mutations in the cohort. This is unique to our cohort, perhaps could even be unique to Asian Indians. Based on this genotype-phenotype correlation in our cohort, we propose an algorithm for genetic prioritisation in Asian Indian PCC/PGL patients (Fig. 1) . Hence, we suggest that complete screening could be replaced by a genetic triaging. However, confirmation of these findings by larger Asian Indian studies would be required.
The only group in our cohort where there was a need to screen patients for more than one gene was apparently sporadic unilateral PCC. To identify all mutations in this group, patients had to be screened for mutations in three genes (VHL, SDHB and SDHD). Recently, nextgeneration sequencing for PCC/PGL susceptibility genes is available in India, the cost of which is similar to that of Sanger sequencing of three common genes. Hence, in future, it would be more useful to perform genetic testing by next-generation sequencing in this particular group of patients. Lack of oligogenicity in our study reiterates that identifying a mutation in one causative gene obviates testing of the remaining genes.
The study also had a few limitations. Due to constrained resources, we could study only five genes. However, these five genes are reported to account for majority of the germline mutations in PCC/PGL, whereas the newer genes account for minority (36, 37, 38) . Referral bias might have been introduced as proportionately more complex cases get referred to tertiary centres, thereby falsely increasing the genetic yield.
Conclusion
In this largest Asian Indian PCC/PGL cohort, 32.7% of total patients and 15.8% with AS presentation had germline mutations. Asian Indians with PCC/PGL differ from Western cohorts in having preponderance of VHL mutations in multifocal tumours and apparently sporadic unilateral PCC. Around 96% mutations in our cohort could be detected by appropriately selected single gene testing. Syndromic presentation, metastasis, location and number of PCC/PGL can be effectively used for guiding genetic prioritisation.
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